> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Selecta Biosciences - URL: https://www.whiteroseintelligence.com/selecta-biosciences/ - Published: 1999-01-02T23:57:00.000Z - Updated: 2025-07-14T04:06:04.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization **Selecta Biosciences, Inc.** is an American biotechnology company based in Watertown, Massachusetts. It trades on the NASDAQ under the ticker name SELB.[\[1\]](#fn1) ## History Selecta Biosciences was founded in 2008 by Omid Farokhzad, after its incorporation in 2007.[\[2\]](#fn2)[\[3\]](#fn3) The company was founded to develop immunomodulatory nanoparticles for the treatment and prevention of human diseases. Early investors in the then-private startup included Polaris Partners and [Flagship Pioneering](https://www.whiteroseintelligence.com/Flagship-Pioneering), the latter of which would soon also launch [Moderna](https://www.whiteroseintelligence.com/Moderna).[\[4\]](#fn4)[\[5\]](#fn5) They were joined in February 2009 by additional investments from NanoDimension and professor Timothy Springer (a founding investor in Moderna).[\[6\]](#fn6) In December 2021, Selecta invested in a Series B funding round for Cyrus Biotechnology.[\[7\]](#fn7) ## Activities The company has had license and collaboration agreements with:[\[3:1\]](#fn3)[\[8\]](#fn8) - Asklepios BioPharmaceutical (AskBio) - Ginkgo Bioworks - IGAN Biosciences - Massachusetts Institute of Technology (MIT) - Sarepta Therapeutics - Shenyang Sunshine Pharmaceutical Co. - Spark Therapeutics - Swedish Orphan Biovitrum (Sobi) - Takeda Pharmaceuticals ### Patents | Number | Title | Date filed | Inventor(s) | | ------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------- | -------------- | ------------------------------------------------- | | [WO2012149411](https://web.archive.org/web/20230204063213/https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012149411) | Controlled release of immunosuppressants from synthetic nanocarriers | April 27, 2012 | David Altreuter, Aaron Griset, Roberto Maldonaldo | ## Organization | Name | Position | Notes | | --------------------- | ------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | Carsten Brunn | President and CEO[\[9\]](#fn9) | [Bayer](https://www.whiteroseintelligence.com/Bayer), European Federation of Pharmaceutical Industries and Associations Japan, [Eli Lilly](https://www.whiteroseintelligence.com/Eli-Lilly), Novartis, Basilea Pharmaceuticals, Bausch & Lomb, Surface Oncology | | Lloyd Johnston | Chief Operations Officer | Alkermes, Advanced Inhalation Research (AIR), University of New South Wales | | Takeshi Kei Kishimoto | Chief Science Officer | Momenta Pharmaceuticals, Millennium Pharmaceuticals, [Boehringer Ingelheim](https://www.whiteroseintelligence.com/Boehringer-Ingelheim) | | Kristen Baldwin | Chief People Officer | LIVEKINDLY Collective, CEO.works, [Bayer](https://www.whiteroseintelligence.com/Bayer), Otsuka Pharmaceuticals | | Peter Traber | Chief Medical Officer | Alacrita Consulting, Morphic Therapeutic, Galectin Therapeutics, GlaxoSmithKline, Baylor College of Medicine, University of Pennsylvania Health System, University of Pennsylvania, Caladrius Biosciences | | Blaine Davis | Chief Financial Officer | Protera Therapeutics, Insmed, Endo International, Endo Ventures, [Bristol-Myers Squibb](https://www.whiteroseintelligence.com/Bristol-Myers-Squibb) | | Matthew Bartholomae | General Counsel, Secretary | Minerva Neurosciences | | Ann Donohue | Vice President of Finance & Controller | \- | | Ulrich von Andrian | Co-Founder and Co-Chair of the Scientific Advisory Board | \- | | Carrie Cox | Chairman | Humacyte, Schering-Plough, Pharmacia & Upjohn, Texas Instruments, Cardinal Health, Organon, Celgene, Array BioPharma, electroCore, Prism Pharmaceutical | | Timothy Barabe | Director | ArQule, Veeva Systems, Vigilant Biosciences, Affymetrix, Human Genome Sciences, Regent Medical, Sandoz | | Nishan de Silva | Director | AFYX Therapeutics, Poseida Therapeutics, Ligand Pharmaceuticals, Warburg Pincus, McKinsey & Company | | Scott Myers | Director | AMAG Pharmaceuticals, Rainier Therapeutics, Cascadian Therapeutics, Aerocrine, UCB, [Johnson & Johnson](https://www.whiteroseintelligence.com/Johnson-&-Johnson), Trillium Therapeutics, Harpoon Therapeutics, Dynavax Technologies | | Aymeric Sallin | Director | NanoDimension, H55, Crocus Technology, Tarveda Therapeutics, Swiss Academy of Engineering Science, École Polytechnique Fédérale de Lausanne (EPFL) | | Timothy Springer | Director | Harvard Medical School, Boston Children's Hospital, LeukoSite, National Academy of Sciences | | Patrick Zenner | Director | Roche, ArQule, West Pharmaceutical Services | | Shuang Sarah Wu | Senior Manager of Strategy and Business Development (former)[\[10\]](#fn10)[\[11\]](#fn11) | Now at [Pfizer](https://www.whiteroseintelligence.com/Pfizer) | ### Investors Companies that have invested in/provided funding for Selecta include:[\[12\]](#fn12)[\[13\]](#fn13)[\[7:1\]](#fn7) - Artal Group - [BlackRock](https://www.whiteroseintelligence.com/BlackRock) - Boxer Capital - EcoR1 Capital - Eminent Venture Capital - Endurant Capital Management - [Flagship Pioneering](https://www.whiteroseintelligence.com/Flagship-Pioneering) - I2BF Global Ventures - JPMorgan Chase - Leukon Investments - Mangrove Partners - Millennium Management - NanoDimension - Osage University Partners (OUP) - Oxford Finance - Polaris Partners - Sanofi Ventures - [Silicon Valley Bank](https://www.whiteroseintelligence.com/Silicon-Valley-Bank) (SVB) - Sphera Funds Management - Vanguard ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=pharmaceutical%5Fcompanies:selecta%5Fbiosciences) - [Crunchbase](https://www.crunchbase.com/organization/selecta-biosciences) - [LinkedIn](https://www.linkedin.com/company/selecta-bio/) - [Twitter](https://twitter.com/selectabio) --- 1. *Selecta Biosciences Inc (SELB) Stock Price & News.* Google Finance. Retrieved February 3, 2023, from [↩︎](#fnref1) 2. *Selecta Biosciences - Crunchbase Company Profile & Funding*. Crunchbase. Retrieved February 3, 2023, from [↩︎](#fnref2) 3. *Selecta Biosciences, Inc. (SELB) Company Profile & Facts.* Yahoo Finance. Retrieved October 16, 2021, from [↩︎](#fnref3) [↩︎](#fnref3:1) 4. Bratzler, R. (2009, February 25). *Selecta Biosciences, Inc. Closes $15.1M Series B Financing.* Flagship Pioneering. [↩︎](#fnref4) 5. *Moderna*. Flagship Pioneering. Retrieved September 15, 2022, from [↩︎](#fnref5) 6. Tognini, G. (2020, May 16). *Exclusive: Meet The Harvard Professor Who Became A Billionaire Thanks To Coronavirus.* Forbes. [↩︎](#fnref6) 7. *Selecta Biosciences - Funding, Financials, Valuation & Investors.* Crunchbase. Retrieved February 3, 2023, from [↩︎](#fnref7) [↩︎](#fnref7:1) 8. *Partnerships*. Selecta Biosciences. Retrieved October 13, 2022, from [↩︎](#fnref8) 9. *About Us.* Selecta Biosciences. Retrieved February 4, 2023, from [↩︎](#fnref9) 10. *SHUANG (SARAH) WU, Gerente Senior, Estrategia y Desarrollo de Negocios, Selecta Biosciences.* GetEmail.io. Retrieved February 3, 2023, from [↩︎](#fnref10) 11. NOSTUPID3\. (2023, January 31). *微博*. Weibo. [↩︎](#fnref11) 12. *Selecta Biosciences, Inc. (SELB) Stock Major Holders.* Yahoo Finance. Retrieved February 3, 2023, from [↩︎](#fnref12) 13. *Companies*. Flagship Pioneering. Retrieved January 15, 2023, from [↩︎](#fnref13)